13 Oct 2022 17:55
CORRECT: Coral Products buys Ecodeck; Evgen Pharma recruits
(Correcting Harmony Energy Income Trust's use of funds.)
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
EVG.L Share News (EVG)
EVG Share
Price
EVG Share
News
EVG Share
Chat
EVG Share
Trades
EVG
Live RNS
EVG Share
Charts
EVG Broker
Ratings
EVG Directors
Deals
EVG Financial
Diary
EVG
Fundamentals
EVG Short
Positions
EVG
Media
EVG.L Information
- There is currently no data for EVG
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.Evgen Pharma receives approval for breast cancer study
Wed, 17th Aug 2016 10:49
(ShareCast News) - Clinical stage drug development company Evgen Pharma announced on Wednesday that it has received a Clinical Trial Approval from the UK's regulatory agency for the commencement of its Phase II clinical trial of SFX-01 in breast cancer.The AIM-traded firm said patient recruitment will begin in the UK at Manchester's Christie NHS Foundation Trust following Research Ethics approval, which is expected during the coming weeks.Further regulatory and Research Ethics approvals are also expected shortly at various sites across Europe for the multi-centre study, the board reported.It said the STEM (SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer) trial will investigate SFX-01 in combination with different hormone-based therapies in 60 metastatic breast cancer patients whose cancer cells are estrogen-receptor positive (ER+).The primary objectives of the STEM trial are to evaluate safety and efficacy via tumour imaging in patients starting to become resistant to mainstream hormone therapy.Patients will be enrolled into one of three study arms - SFX-01 in combination with either aromatase inhibitors, tamoxifen or fulvestrant - based on their current therapy.It will be led by chief investigator Dr Sacha Howell at Manchester's Christie NHS Foundation Trust, Europe's largest single-site cancer centre, and include several other sites across Europe.The company says first patient is expected to be recruited in October 2016."Many therapies used in cancer ultimately fail as patients develop resistance - one hypothesis is that this resistance is driven by cancer stem cells which, unlike a mature cancer cell, do not respond to current standards of care," said Evgen CEO Dr Stephen Franklin."Our excitement with SFX-01 is that it targets the cancer stem cell population and therefore has the potential to improve the efficacy and longevity of a range of drugs used in cancer therapy - both approved drugs and those in clinical development."
More News
12 Oct 2022 21:46
TRADING UPDATES: Coral Products buys Ecodeck; Evgen Pharma recruits
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:
Read more12 Oct 2022 12:23
Evgen starts recruiting volunteers for trial of lead asset
(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced the start of recruitment for the pharmacokinetic and pharmacodynamic trial in healthy volunteers, and the decision to commence an investigator-sponsored clinical study for the glioblastoma programme on Wednesday.
Read more10 Oct 2022 12:10
LONDON MARKET MIDDAY: FTSE 100 trims opening loss amid Fed hike worry
(Alliance News) - European equities traded off session lows heading into Monday afternoon, finding some poise after a poor open, as markets deal with the fallout from last week's US jobs report.
Read more10 Oct 2022 11:00
AIM WINNERS & LOSERS: Europa Oil, i3 Energy slide as well disappoints
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.
Read more10 Oct 2022 09:58
Evgen Pharma shares jump 65% as licences SFX-01 composition for autism
(Alliance News) - Evgen Pharma PLC on Monday said it has signed a licencing deal for up to USD160.5 million with Stalicla SA for the global rights to its lead asset SFX-01 in neurodevelopmental disorders and schizophrenia.
Read more14 Jul 2022 16:39
UK shareholder meetings calendar - next 7 days
| Friday 15 July | |
| Aveva Group PLC | AGM |
| DCC PLC | AGM |
| DP Poland PLC | AGM |
| Griffin Mining Ltd | AGM |
| MC Mining PLC | GM re subscription |
| Monday 18 July | |
| Audioboom Group PLC | AGM |
| JPMorgan European Discovery Trust PLC | AGM |
| Tuesday 19 July | |
| Biotech Growth Trust PLC | AGM |
| Clean Power Hydrogen PLC | AGM |
| e-Therapeutics PLC | AGM |
| Norcros PLC | AGM |
| Ten Lifestyle Group PLC | GE re commitment to sustainability, B Corp certification |
| Wednesday 20 July | |
| ADM Energy PLC | AGM |
| Alkemy Capital Investments PLC | AGM |
| DeepVerge PLC | AGM |
| easyJet PLC | GM re purchase of 56 Airbus A320neo family aircraft & conversion of 18 A320neo family aircraft |
| Fidelity China Special Situations PLC | AGM |
| HarbourVest Global Private Equity Ltd | AGM |
| HICL Infrastructure PLC | AGM |
| Novacyt SA | AGM r |
| Plaza Centers NV | AGM |
| Premier Foods PLC | AGM |
| Royal Mail PLC | AGM |
| Triad Group PLC | AGM |
| Wynnstay Properties PLC | AGM & GM re share buyback |
| Thursday 21 July | |
| Big Yellow Group PLC | AGM |
| Evgen Pharma PLC | AGM |
| Experian PLC | AGM |
| Halma PLC | AGM |
| Intermediate Capital Group PLC | AGM |
| Johnson Matthey PLC | AGM |
| Octopus AIM VCT PLC | AGM |
| Pennon Group PLC | AGM |
| Pires Investments PLC | GM re offer from Tern PLC |
| QinetiQ Group PLC | AGM |
| SSE PLC | AGM |
| Tern PLC | GM re offer for Pires Investments PLC |
| Vp PLC | AGM |
| Workspace Group PLC | AGM |
| Zephyr Energy PLC | AGM |
| Copyright 2022 Alliance News Limited. All Rights Reserved. | |
13 Jun 2022 19:22
IN BRIEF: Evgen to work with University of Michigan on asset SFX-01
Evgen Pharma PLC- Cheshire, England-based drug development company - Announces collaboration with University of Michigan, to investigate the potential anti-tumour effects of the company's lead asset SFX-01 in colorectal cancer.
Read more8 Jun 2022 14:26
Evgen Pharma starts trial to test breast cancer tablet; loss narrows
(Alliance News) - Evgen Pharma PLC on Wednesday said it would begin a trial to test a new medicinal product later this year and said its results for the most recent financial year are in line with expectations.
Read more25 May 2022 22:02
TRADING UPDATES: Tekcapital fundraise; Kromek wins US government order
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:
Read more18 Jan 2022 11:48
Evgen agrees fresh licensing deal with Spanish institutions
(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced a memorandum of understanding with the University of Seville, Consejo Superior de Investigaciones Científicas (CSIC) and Fundación Pública Andaluza Progreso y Salud on behalf of the Institute of Biomedicine of Seville on Tuesday, for second-generation sulforaphane analogues.
Read more18 Jan 2022 11:32
Evgen signs agreement for Spanish institutions' sulfoaphane analogues
Evgen signs agreement for Spanish institutions' sulfoaphane analogues
Read more7 Dec 2021 21:49
EARNINGS UPDATES: Carr's beats expectations; Premier assets hit record
EARNINGS UPDATES: Carr's beats expectations; Premier assets hit record
Read more30 Nov 2021 16:26
UK earnings, trading statements calendar - next 7 days
UK earnings, trading statements calendar - next 7 days
Read more10 Nov 2021 18:22
TRADING UPDATES: Permanent TSB sells loan portfolio; Dekel output up
TRADING UPDATES: Permanent TSB sells loan portfolio; Dekel output up
Read more